These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 9264766

  • 1. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
    de la Taille A, Houlgatte A, Houdelette P, Berlizot P, Ramirez J, Ricordel I.
    Prog Urol; 1997 Apr; 7(2):240-5. PubMed ID: 9264766
    [Abstract] [Full Text] [Related]

  • 2. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, Wright GL, Schellhammer PF, Weigand RA, Olson RM, Dowell BL, Borden KK, Oesterling JE.
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [Abstract] [Full Text] [Related]

  • 3. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
    de La Taille A, Houlgatte A, Houdelette P, Berlizot P, Fournier R, Ricordel I.
    Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
    [Abstract] [Full Text] [Related]

  • 4. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J, Raventós CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, Andreu J.
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [Abstract] [Full Text] [Related]

  • 5. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M.
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [Abstract] [Full Text] [Related]

  • 6. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B, Alkibay T, Tuncel A, Bozkirli I.
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW.
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 10. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W, Stieber P, Schmeller N, Nagel D, Hofmann K, Fateh-Moghadam A.
    Anticancer Res; 1997 Dec 15; 17(6D):4759-65. PubMed ID: 9494603
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
    Kobayashi T, Kamoto T, Nishizawa K, Mitsumori K, Ogura K, Ide Y.
    BJU Int; 2005 Apr 15; 95(6):761-5. PubMed ID: 15794778
    [Abstract] [Full Text] [Related]

  • 13. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H.
    J Urol; 2004 Jan 15; 171(1):182-6. PubMed ID: 14665872
    [Abstract] [Full Text] [Related]

  • 14. [The percentage of free prostate specific antigen used in detecting prostate cancer].
    Yang L, Fang Z, Song J, Deng S.
    Zhonghua Wai Ke Za Zhi; 1999 Jan 15; 37(1):47-9. PubMed ID: 11829778
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X, Alcover J, Corral JM, Molina R, Beardo P, Ballesta AM.
    Anticancer Res; 2001 Jan 15; 21(5):3717-20. PubMed ID: 11848550
    [Abstract] [Full Text] [Related]

  • 18. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
    Wolff JM, Boeckmann W, Effert PJ, Habib FK, Jakse G.
    Anticancer Res; 1997 Jan 15; 17(4B):2993-4. PubMed ID: 9329583
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
    Egawa S, Soh S, Ohori M, Uchida T, Gohji K, Fujii A, Kuwao S, Koshiba K.
    Cancer; 1997 Jan 01; 79(1):90-8. PubMed ID: 8988731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.